GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.18
−0.17%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+0.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 26, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 25 | $0.00 |
| Aug 26, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 5,800,051 | $0.17 |
| Aug 26, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 166 | $0.00 |
| Aug 26, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 5,800,051 | $0.17 |
| Aug 26, 2026 | Christian Waage · officer: EVP, Tech Ops and Admin | A-Award | 2,900,026 | $0.17 |
| Aug 26, 2026 | Peterson Caryn · officer: Chief Development Officer | A-Award | 5,800,051 | $0.17 |
| Aug 26, 2026 | Smith Robert Paul JR · officer: Chief Commercial Officer | A-Award | 5,800,051 | $0.17 |
| Jun 5, 2026 | Cox Russell J. · director | A-Award | 115,000 | $0.18 |
| Jun 5, 2026 | Milligan Sandra · director | A-Award | 115,000 | $0.18 |
| Jun 5, 2026 | Nathan Steven D · director | A-Award | 115,000 | $0.18 |
| Jun 5, 2026 | Quisel John D · director | A-Award | 115,000 | $0.18 |
| Jun 5, 2026 | Drynan Skye · director | A-Award | 115,000 | $0.18 |
| Jun 5, 2026 | Daniel Thomas O · director | A-Award | 115,000 | $0.18 |
| Mar 20, 2026 | Aranda Richard · officer: Chief Medical Officer | A-Award | 157,500 | $0.45 |
| Mar 20, 2026 | Aranda Richard · officer: Chief Medical Officer | A-Award | 487,500 | $0.45 |
| Mar 20, 2026 | Aranda Richard · officer: Chief Medical Officer | A-Award | 572,000 | $0.45 |
| Mar 20, 2026 | Aranda Richard · officer: Chief Medical Officer | A-Award | 562,500 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 176,667 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 211,500 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 181,250 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 543,750 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 638,000 | $0.45 |
| Mar 20, 2026 | Giraudo Bryan · officer: COO/CFO | A-Award | 693,750 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 43,500 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 47,000 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 325,000 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 650,000 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 544,500 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 437,500 | $0.45 |
| Mar 20, 2026 | Hasnain Faheem · director, officer: President & CEO | A-Award | 1,312,500 | $0.45 |
Institutional positioning
13F filings over the trailing two quarters
New 49Increased 69Reduced 59Sold out 193
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Reduced | 16,826,695 | May 13, 2026 |
| Kalehua Capital Management LLC | New Position | 10,236,293 | May 15, 2026 |
| AQR CAPITAL MANAGEMENT LLC | Increased | 10,126,897 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 9,394,593 | May 15, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 8,055,916 | May 15, 2026 |
| OCTAGON CAPITAL ADVISORS LP | Reduced | 7,750,000 | May 15, 2026 |
| SAMSARA BIOCAPITAL, LLC | Unchanged | 7,222,559 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 5,922,298 | May 15, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | Increased | 5,277,904 | May 13, 2026 |
| SIREN, L.L.C. | Unchanged | 5,208,968 | May 14, 2026 |
| 683 CAPITAL MANAGEMENT, LLC | Reduced | 5,000,000 | May 15, 2026 |
| HHLR ADVISORS, LTD. | Unchanged | 4,974,041 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 4,939,691 | May 15, 2026 |
| QUBE RESEARCH & TECHNOLOGIES LTD | Increased | 4,917,763 | May 15, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 4,780,851 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 26, 2026